Goldman initiated coverage on Stryker with a new price target
$SYK
Medical/Dental Instruments
Health Care
Goldman initiated coverage of Stryker with a rating of Neutral and set a new price target of $372.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/10/2024 | $405.00 | Outperform | Wolfe Research |
| 5/30/2024 | $372.00 | Neutral | Goldman |
| 5/22/2024 | $392.00 | Hold → Buy | Needham |
| 1/31/2024 | $315.00 → $360.00 | Hold → Buy | Canaccord Genuity |
| 10/20/2023 | $345.00 | Buy | ROTH MKM |
| 9/5/2023 | $310.00 → $315.00 | Neutral → Buy | BofA Securities |
| 3/29/2023 | $287.00 | Neutral | UBS |
| 1/25/2023 | Sector Weight | KeyBanc Capital Markets |
FLOWER MOUND, Texas, USA, Nov. 19, 2024 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, unveiled the Oculan Lighting Platform, an innovative lighting solution designed to provide consistent, high-quality illumination, allowing surgeons to focus on delivering the highest standard of care. In today's operating rooms, where precision and accuracy are critical, even the smallest challenges may impact surgical outcomes – factors which may impede a surgeon's ability to see clearly and work efficiently. "The Oculan Lighting Platform was developed in respo
PORTAGE, Mich., USA, Nov. 14, 2024 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, announced its launch of the next generation of SurgiCount+ within its sponge management portfolio. Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals. Maternal mortality has been rising in the U.S. for decades,1 with approximately 50,000 c
Portage, Michigan, Oct. 29, 2024 (GLOBE NEWSWIRE) -- reported operating results for the third quarter of 2024: Third Quarter Results Reported net sales increased 11.9% to $5.5 billionOrganic net sales increased 11.5%Reported operating income margin of 19.7%Adjusted operating income margin(1) increased 130 bps to 24.7%Reported EPS increased 20.0% to $2.16Adjusted EPS(1) increased 16.7% to $2.87 Third Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acquisitions / Divestitures OrganicMedSurg and Neurotechnology 12.8 % (0.1) % 12.9 % 0.2 % 12.7 %Orthopaedics and Spine 10.7
Stryker's (NYSE:SYK) short percent of float has risen 7.55% since its last report. The company recently reported that it has 4.11 million shares sold short, which is 1.14% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.41 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short interest is impo
Stryker (NYSE:SYK) has outperformed the market over the past 10 years by 4.7% on an annualized basis producing an average annual return of 15.6%. Currently, Stryker has a market capitalization of $130.48 billion. Buying $1000 In SYK: If an investor had bought $1000 of SYK stock 10 years ago, it would be worth $4,267.32 today based on a price of $342.50 for SYK at the time of writing. Stryker's Performance Over Last 10 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and reviewed
Morgan Stanley analyst Drew Ranieri maintains Stryker (NYSE:SYK) with a Equal-Weight and raises the price target from $345 to $350.
Mr. Scannell and Ms. Lane will Add Valuable Medical Technology, Finance and Corporate Governance Experience to Expanded Eight-Member Board Masimo Corporation (NASDAQ:MASI), a leading global medical innovator, today announced the appointments of Timothy J. Scannell and Wendy E. Lane to the Company's Board of Directors (the "Board"), effective immediately. Following these appointments, the Board will consist of eight directors. Quentin Koffey, Lead Independent Director of Masimo, stated, "We are pleased to welcome Tim and Wendy as our newest independent directors. Both are high-caliber professionals who will bring critical perspectives to the Board and possess expertise that closely aligns
EMERYVILLE, Calif., Sept. 12, 2024 /PRNewswire/ -- Eko Health, a pioneer in applying artificial intelligence (AI) for early detection of heart and lung diseases, today announced the appointment of Brent D. Lang, former Chairman and CEO of Vocera Communications, to its Board of Directors. Lang brings over three decades of healthcare and technology experience, having led Vocera through rapid growth, a successful IPO, and its $3 billion acquisition by Stryker (NYSE:SYK). His strategic vision and proven leadership will guide Eko as it continues to innovate and expand its platform
Sends Letter to Masimo Shareholders and Releases 160-Page Investor Presentation Urges Shareholders to Help Deliver Immediate Change by Voting for Both of Politan's Independent and Ideally Qualified Nominees Darlene Solomon and William Jellison on the WHITE Card Shareholders Can Visit www.AdvanceMasimo.com for Further Information Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today sent a letter to the Company's shareholders outlining why a majority of truly independent directors are urgently needed in the Masimo boardroom. Politan also released a detailed investor presentation m
10-Q - STRYKER CORP (0000310764) (Filer)
8-K - STRYKER CORP (0000310764) (Filer)
CERT - STRYKER CORP (0000310764) (Filer)
Wolfe Research initiated coverage of Stryker with a rating of Outperform and set a new price target of $405.00
Goldman initiated coverage of Stryker with a rating of Neutral and set a new price target of $372.00
Needham upgraded Stryker from Hold to Buy and set a new price target of $392.00
4 - STRYKER CORP (0000310764) (Issuer)
4 - STRYKER CORP (0000310764) (Issuer)
4 - STRYKER CORP (0000310764) (Issuer)
Portage, Michigan, Oct. 29, 2024 (GLOBE NEWSWIRE) -- reported operating results for the third quarter of 2024: Third Quarter Results Reported net sales increased 11.9% to $5.5 billionOrganic net sales increased 11.5%Reported operating income margin of 19.7%Adjusted operating income margin(1) increased 130 bps to 24.7%Reported EPS increased 20.0% to $2.16Adjusted EPS(1) increased 16.7% to $2.87 Third Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acquisitions / Divestitures OrganicMedSurg and Neurotechnology 12.8 % (0.1) % 12.9 % 0.2 % 12.7 %Orthopaedics and Spine 10.7
Portage, Michigan, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced today that it has completed the acquisition of Vertos Medical Inc., a leader in interventional pain management solutions for chronic lower back pain caused by lumbar spinal stenosis. "The acquisition of Vertos Medical enhances our unique, non-surgical solutions for interventionalists addressing chronic lower back pain, while broadening our presence in ambulatory surgery centers," said Andy Pierce, Group President, MedSurg and Neurotechnology, Stryker. "We look forward to enabling physicians with the minimally invasive mild® procedure so patients can reclaim their quality of life." The addition of Vertos Me
PORTAGE, Mich., USA, Sept. 20, 2024 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, announced today that it has completed the acquisition of NICO Corporation, a privately held company providing a systematic approach to minimally invasive surgery for tumor and intracerebral hemorrhage (ICH) procedures. This acquisition further strengthens Stryker's commitment to neurotechnology through tumor and stroke care. ICH, or bleeding in the brain caused by a ruptured blood vessel, is the deadliest form of stroke, affecting over 3.4 million people annually ar
SC 13G/A - STRYKER CORP (0000310764) (Subject)
SC 13G/A - STRYKER CORP (0000310764) (Subject)
SC 13G/A - STRYKER CORP (0000310764) (Subject)